EVAX Quote, Financials, Valuation and Earnings

Ascendis Pharma A/S has a net margin of -64.14% compared to Evaxion AS's net margin of -13.56%. Evaxion AS's return on equity of -80.26% beat Ascendis Pharma A/S's return on equity of -880.05%.

Evaxion AS has a consensus price target of $11.25, signalling upside risk potential of 197.62%. On the other hand Ascendis Pharma A/S has an analysts' consensus of $289.08 which suggests that it could grow by 25.56%. Given that Evaxion AS has higher upside potential than Ascendis Pharma A/S, analysts believe Evaxion AS is more attractive than Ascendis Pharma A/S.

Evaxion AS has a beta of 0.187, which suggesting that the stock is 81.283% less volatile than S&P 500. In comparison Ascendis Pharma A/S has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.982%.

Evaxion AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ascendis Pharma A/S offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evaxion AS pays -- of its earnings as a dividend. Ascendis Pharma A/S pays out -- of its earnings as a dividend.

Evaxion AS quarterly revenues are --, which are smaller than Ascendis Pharma A/S quarterly revenues of $288.1M. Evaxion AS's net income of -$5.9M is higher than Ascendis Pharma A/S's net income of -$39.1M. Notably, Evaxion AS's price-to-earnings ratio is -- while Ascendis Pharma A/S's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion AS is 3.13x versus 16.96x for Ascendis Pharma A/S. Usually stocks with elevated PS ratios are considered overvalued.

Cellectis SA has a net margin of -64.14% compared to Evaxion AS's net margin of -253.13%. Evaxion AS's return on equity of -80.26% beat Cellectis SA's return on equity of -65.19%.

Evaxion AS has a consensus price target of $11.25, signalling upside risk potential of 197.62%. On the other hand Cellectis SA has an analysts' consensus of $7.25 which suggests that it could grow by 112.61%. Given that Evaxion AS has higher upside potential than Cellectis SA, analysts believe Evaxion AS is more attractive than Cellectis SA.

Evaxion AS has a beta of 0.187, which suggesting that the stock is 81.283% less volatile than S&P 500. In comparison Cellectis SA has a beta of 2.907, suggesting its more volatile than the S&P 500 by 190.653%.

Evaxion AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evaxion AS pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

Evaxion AS quarterly revenues are --, which are smaller than Cellectis SA quarterly revenues of $10.4M. Evaxion AS's net income of -$5.9M is higher than Cellectis SA's net income of -$26.3M. Notably, Evaxion AS's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion AS is 3.13x versus 4.70x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of -64.14% compared to Evaxion AS's net margin of --. Evaxion AS's return on equity of -80.26% beat DBV Technologies SA's return on equity of -217.87%.

Evaxion AS has a consensus price target of $11.25, signalling upside risk potential of 197.62%. On the other hand DBV Technologies SA has an analysts' consensus of $39.89 which suggests that it could grow by 89.39%. Given that Evaxion AS has higher upside potential than DBV Technologies SA, analysts believe Evaxion AS is more attractive than DBV Technologies SA.

Evaxion AS has a beta of 0.187, which suggesting that the stock is 81.283% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.942, suggesting its less volatile than the S&P 500 by 194.186%.

Evaxion AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evaxion AS pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Evaxion AS quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Evaxion AS's net income of -$5.9M is higher than DBV Technologies SA's net income of -$44.8M. Notably, Evaxion AS's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion AS is 3.13x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk A/S has a net margin of -64.14% compared to Evaxion AS's net margin of 33.98%. Evaxion AS's return on equity of -80.26% beat Novo Nordisk A/S's return on equity of 62.44%.

Evaxion AS has a consensus price target of $11.25, signalling upside risk potential of 197.62%. On the other hand Novo Nordisk A/S has an analysts' consensus of $47.36 which suggests that it could grow by 28.08%. Given that Evaxion AS has higher upside potential than Novo Nordisk A/S, analysts believe Evaxion AS is more attractive than Novo Nordisk A/S.

Evaxion AS has a beta of 0.187, which suggesting that the stock is 81.283% less volatile than S&P 500. In comparison Novo Nordisk A/S has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.371%.

Evaxion AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk A/S offers a yield of 4.81% to investors and pays a quarterly dividend of $1.22 per share. Evaxion AS pays -- of its earnings as a dividend. Novo Nordisk A/S pays out 36.87% of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Evaxion AS quarterly revenues are --, which are smaller than Novo Nordisk A/S quarterly revenues of $12.3B. Evaxion AS's net income of -$5.9M is lower than Novo Nordisk A/S's net income of $4.2B. Notably, Evaxion AS's price-to-earnings ratio is -- while Novo Nordisk A/S's PE ratio is 10.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion AS is 3.13x versus 3.52x for Novo Nordisk A/S. Usually stocks with elevated PS ratios are considered overvalued.